Lipoic acid

Physical and chemical properties

Lipoic acid contains two sulfur atoms connected by a disulfide bond in the 1,2-dithiolane ring. It also carries a carboxylic acid group. It is considered to be oxidized relative to its acyclic relative dihydrolipoic acid, in which each sulfur exists as a thiol. It is a yellow solid.

(R)-(+)-lipoic acid (RLA) occurs naturally, but (S)-(-)-lipoic acid (SLA) has been synthesized.

For use in dietary supplement materials and compounding pharmacies, the USP established an official monograph for R/S-LA.

Biological function

Lipoic acid is a cofactor for five enzymes or classes of enzymes: pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, the glycine cleavage system, branched-chain alpha-keto acid dehydrogenase, and the α-oxo(keto)adipate dehydrogenase. The first two are critical to the citric acid cycle. The GCS regulates glycine concentrations.

HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are targets of the reduced form (open dithiol) of (R)-lipoic acid.

Biosynthesis and attachment

Most endogenously produced RLA are not "free" because octanoic acid, the precursor to RLA, is bound to the enzyme complexes prior to enzymatic insertion of the sulfur atoms. As a cofactor, RLA is covalently attached by an amide bond to a terminal lysine residue of the enzyme's lipoyl domains. The precursor to lipoic acid, octanoic acid, is made via mitochondrial fatty acid biosynthesis in the form of octanoyl-acyl carrier protein. Free lipoate can be used by some organisms as an enzyme called lipoate protein ligase that attaches it covalently to the correct protein. The ligase activity of this enzyme requires ATP.

Cellular transport

Along with sodium and the vitamins biotin (B7) and pantothenic acid (B5), lipoic acid enters cells through the SMVT (sodium-dependent multivitamin transporter). Each of the compounds transported by the SMVT is competitive with the others. For example research has shown that increasing intake of lipoic acid or pantothenic acid reduces the uptake of biotin and/or the activities of biotin-dependent enzymes.

Enzymatic activity

Lipoic acid is a cofactor for at least five enzyme systems. Two of these are in the citric acid cycle through which many organisms turn nutrients into energy. Lipoylated enzymes have lipoic acid attached to them covalently. The lipoyl group transfers acyl groups in 2-oxoacid dehydrogenase complexes, and methylamine group in the glycine cleavage complex or glycine dehydrogenase.

Lipoic acid is the cofactor of the following enzymes in humans:

The most-studied of these is the pyruvate dehydrogenase complex.

Lipoic acid serves as co-factor to the acetoin dehydrogenase complex catalyzing the conversion of acetoin (3-hydroxy-2-butanone) to acetaldehyde and acetyl coenzyme A.

The glycine cleavage system differs from the other complexes, and has a different nomenclature.

Biological sources and degradation

Lipoic acid is present in many foods in which it is bound to lysine in proteins, Naturally occurring lipoic acid is always covalently bound and not readily available from dietary sources. As a result, all lipoic acid available as a supplement is chemically synthesized.

Baseline levels (prior to supplementation) of RLA and R-DHLA have not been detected in human plasma. RLA has been detected at 12.3−43.1 ng/mL following acid hydrolysis, which releases protein-bound lipoic acid. Enzymatic hydrolysis of protein bound lipoic acid released 1.4−11.6 ng/mL and

Digestive proteolytic enzymes cleave the R-lipoyllysine residue from the mitochondrial enzyme complexes derived from food but are unable to cleave the lipoic acid-L-lysine amide bond. Both synthetic lipoamide and (R)-lipoyl-L-lysine are rapidly cleaved by serum lipoamidases, which release free (R)-lipoic acid and either L-lysine or ammonia. Little is known about the degradation and utilization of aliphatic sulfides such as lipoic acid, except for cysteine.

Lipoic acid is metabolized in a variety of ways when given as a dietary supplement in mammals. Degradation to tetranorlipoic acid, oxidation of one or both of the sulfur atoms to the sulfoxide, and S-methylation of the sulfide were observed. Conjugation of unmodified lipoic acid to glycine was detected especially in mice. Degradation of lipoic acid is similar in humans, although it is not clear if the sulfur atoms become significantly oxidized. Apparently mammals are not capable of utilizing lipoic acid as a sulfur source.

Diseases

Combined malonic and methylmalonic aciduria (CMAMMA)

In the metabolic disease combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, mitochondrial fatty acid synthesis (mtFAS), which is the precursor reaction of lipoic acid biosynthesis, is impaired. The result is a reduced lipoylation degree of important mitochondrial enzymes, such as pyruvate dehydrogenase complex (PDC) and α-ketoglutarate dehydrogenase complex (α-KGDHC). Supplementation with lipoic acid does not restore mitochondrial function.

Chemical synthesis

SLA did not exist prior to chemical synthesis in 1952. SLA is produced in equal amounts with RLA during achiral manufacturing processes. The racemic form was more widely used clinically in Europe and Japan in the 1950s to 1960s despite the early recognition that the various forms of LA are not bioequivalent. The first synthetic procedures appeared for RLA and SLA in the mid-1950s. Advances in chiral chemistry led to more efficient technologies for manufacturing the single enantiomers by both classical resolution and asymmetric synthesis and the demand for RLA also grew at this time. In the 21st century, R/S-LA, RLA and SLA with high chemical and/or optical purities are available in industrial quantities. At the current time, most of the world supply of R/S-LA and RLA is manufactured in China and smaller amounts in Italy, Germany, and Japan. RLA is produced by modifications of a process first described by Georg Lang in a Ph.D. thesis and later patented by Degussa. Although RLA is favored nutritionally due to its "vitamin-like" role in metabolism, both RLA and R/S-LA are widely available as dietary supplements. Both stereospecific and non-stereospecific reactions are known to occur in vivo and contribute to the mechanisms of action, but evidence to date indicates RLA may be the eutomer (the nutritionally and therapeutically preferred form).

Pharmacology

Pharmacokinetics

A 2007 human pharmacokinetic study of sodium RLA demonstrated the maximum concentration in plasma and bioavailability are significantly greater than the free acid form, and rivals plasma levels achieved by intravenous administration of the free acid form. Additionally, high plasma levels comparable to those in animal models where Nrf2 was activated were achieved.

The various forms of LA are not bioequivalent. Very few studies compare individual enantiomers with racemic lipoic acid. It is unclear if twice as much racemic lipoic acid can replace RLA.

The toxic dose of LA in cats is much lower than that in humans or dogs and produces hepatocellular toxicity.

Pharmacodynamics

The mechanism and action of lipoic acid when supplied externally to an organism is controversial. Lipoic acid in a cell seems primarily to induce the oxidative stress response rather than directly scavenge free radicals. This effect is specific for RLA. Despite the strongly reducing milieu, LA has been detected intracellularly in both oxidized and reduced forms. LA is able to scavenge reactive oxygen and reactive nitrogen species in a biochemical assay due to long incubation times, but there is little evidence this occurs within a cell or that radical scavenging contributes to the primary mechanisms of action of LA. The relatively good scavenging activity of LA toward hypochlorous acid (a bactericidal produced by neutrophils that may produce inflammation and tissue damage) is due to the strained conformation of the 5-membered dithiolane ring, which is lost upon reduction to DHLA. In cells, LA is reduced to dihydrolipoic acid, which is generally regarded as the more bioactive form of LA and the form responsible for most of the antioxidant effects and for lowering the redox activities of unbound iron and copper. This theory has been challenged due to the high level of reactivity of the two free sulfhydryls, low intracellular concentrations of DHLA as well as the rapid methylation of one or both sulfhydryls, rapid side-chain oxidation to shorter metabolites and rapid efflux from the cell. Although both DHLA and LA have been found inside cells after administration, most intracellular DHLA probably exists as mixed disulfides with various cysteine residues from cytosolic and mitochondrial proteins. Recent findings suggest therapeutic and anti-aging effects are due to modulation of signal transduction and gene transcription, which improve the antioxidant status of the cell. However, this likely occurs via pro-oxidant mechanisms, not by radical scavenging or reducing effects.

All the disulfide forms of LA (R/S-LA, RLA and SLA) can be reduced to DHLA although both tissue specific and stereoselective (preference for one enantiomer over the other) reductions have been reported in model systems. At least two cytosolic enzymes, glutathione reductase (GR) and thioredoxin reductase (Trx1), and two mitochondrial enzymes, lipoamide dehydrogenase and thioredoxin reductase (Trx2), reduce LA. SLA is stereoselectively reduced by cytosolic GR whereas Trx1, Trx2 and lipoamide dehydrogenase stereoselectively reduce RLA. (R)-(+)-lipoic acid is enzymatically or chemically reduced to (R)-(-)-dihydrolipoic acid whereas (S)-(-)-lipoic acid is reduced to (S)-(+)-dihydrolipoic acid. Dihydrolipoic acid (DHLA) can also form intracellularly and extracellularly via non-enzymatic, thiol-disulfide exchange reactions.

RLA may function in vivo like a B-vitamin and at higher doses like plant-derived nutrients, such as curcumin, sulforaphane, resveratrol, and other nutritional substances that induce phase II detoxification enzymes, thus acting as cytoprotective agents. This stress response indirectly improves the antioxidant capacity of the cell.

The (S)-enantiomer of LA was shown to be toxic when administered to thiamine-deficient rats.

Several studies have demonstrated that SLA either has lower activity than RLA or interferes with the specific effects of RLA by competitive inhibition.

Uses

R/S-LA and RLA are widely available as over-the-counter nutritional supplements in the United States in the form of capsules, tablets, and aqueous liquids, and have been marketed as antioxidants and pertaining to cellular glucose utilization for metabolic disorders and type 2 diabetes.

Although the body can synthesize LA, it can also be absorbed from the diet. Dietary supplementation in doses from 200–600 mg is likely to provide up to 1000 times the amount available from a regular diet. Gastrointestinal absorption is variable and decreases with the use of food. It is therefore recommended that dietary LA be taken 30–60 minutes before or at least 120 minutes after a meal. Maximum blood levels of LA are achieved 30–60 minutes after dietary supplementation, and it is thought to be largely metabolized in the liver.

In Germany, LA is approved as a drug for the treatment of diabetic neuropathy since 1966 and is available as a non-prescription pharmaceutical.

Clinical research

According to the American Cancer Society as of 2013, "there is no reliable scientific evidence at this time that lipoic acid prevents the development or spread of cancer".

As of 2015, intravenously administered ALA is unapproved anywhere in the world except Germany for diabetic neuropathy, but has been proven reasonably safe and effective. As of 2012, there was no good evidence alpha lipoic acid helps people with mitochondrial disorders.

A 2018 review found that ALA had a small effect to reduce body weight, but is not cost-effective as a dietary supplement.

A 2025 study indicated a positive effect in a cellular model of Friedreich Ataxia.

Other lipoic acids

• β-lipoic acid is a thiosulfinate of α-lipoic acid

References

References

1. . ["Lipoic Acid"](https://pubchem.ncbi.nlm.nih.gov/compound/thioctic_acid#section=Physical-Description). *NCBI*.
2. (November 2003). "Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers". [[The Journal of Clinical Pharmacology]].
3. (1 January 2019). "Lipoic acid". Micronutrient Information Center, Linus Pauling Institute, Oregon State University, Corvallis.
4. "USP32-NF27".
5. . (February 2009). ["Unavailable First-Time Official USP Reference Standards"](https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/pf-legacy-pdf/pf-2009_vol-35.pdf). *USP*.
6. (2020). "Progress in the Enzymology of the Mitochondrial Diseases of Lipoic Acid Requiring Enzymes". Frontiers in Genetics.
7. (2023). "Chemoproteomic target deconvolution reveals Histone Deacetylases as targets of (R)-lipoic acid". Nature Communications.
8. (2005). "Expression cloning and demonstration of ''Enterococcus faecalis'' lipoamidase (pyruvate dehydrogenase inactivase) as a Ser-Ser-Lys triad amidohydrolase". [[Journal of Biological Chemistry]].
9. (1997). "Lipoic acid reduces the activities of biotin-dependent carboxylases in rat liver". The Journal of Nutrition.
10. (2013). "High specificity in response of the sodium-dependent multivitamin transporter to derivatives of pantothenic acid". Current Topics in Medicinal Chemistry.
11. (2014). "Lipoic acid biosynthesis defects". Journal of Inherited Metabolic Disease.
12. (2018). "Lipoic acid metabolism and mitochondrial redox regulation". Journal of Biological Chemistry.
13. (2022-07-26). "Functional Versatility of the Human 2-Oxoadipate Dehydrogenase in the L-Lysine Degradation Pathway toward Its Non-Cognate Substrate 2-Oxopimelic Acid". International Journal of Molecular Sciences.
14. (1996). "Enantioselective pharmacokinetics and bioavailability of different racemic formulations in healthy volunteers". [[European Journal of Pharmaceutical Sciences]].
15. (1997). "Vitamins and Coenzymes Part I".
16. (October 1995). "Determination of lipoic acid in human plasma by high-performance liquid chromatography with electrochemical detection". [[Journal of Chromatography B]].
17. (November 1992). "HPLC-methods for determination of lipoic acid and its reduced form in human plasma". International Journal of Clinical Pharmacology, Therapy, and Toxicology.
18. (September 1997). "The pharmacology of the antioxidant lipoic acid". General Pharmacology.
19. (2019). "Combined malonic and methylmalonic aciduria due to ACSF3 mutations: Benign clinical course in an unselected cohort". Journal of Inherited Metabolic Disease.
20. (2019-11-01). "The emerging role of the mitochondrial fatty-acid synthase (mtFASII) in the regulation of energy metabolism". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.
21. (2010). "Mitochondrial fatty acid synthesis and respiration". Biochimica et Biophysica Acta (BBA) - Bioenergetics.
22. (1953). "Synthesis of DL—lipoic acid". [[Journal of the American Chemical Society]].
23. (1952). "Synthetic preparation of lipoic acid". [[Journal of the American Chemical Society]].
24. (1955). "Preparation of optical antipodes of alpha-lipoic acid". Il Farmaco; Edizione Scientifica.
25. (1955). "Synthesis of (+)-lipoic acid and its optical antipode". [[Journal of the American Chemical Society]].
26. (1957). "Optically active and radioactive α-lipoic acids". [[Journal of the American Chemical Society]].
27. (June 1964). "Studies on the synthesis of thioctic acid and its related compounds. XIV. Synthesis of (+)-thioctamide". Yakugaku Zasshi.
28. Lang, G. (1992). "In Vitro Metabolism of a-Lipoic Acid Especially Taking Enantioselective Bio-transformation into Account". University of Münster.
29. "Preparation and use of salts of the pure enantiomers of alpha-lipoic acid".
30. (October 2001). "Molecular aspects of lipoic acid in the prevention of diabetes complications". Nutrition.
31. (December 2007). "The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects". Alternative Medicine Review.
32. (1991). "Thioctsäure: Neue Biochemische, Pharmakologische und Klinische Erkenntnisse zur Thioctsäure". Verlag.
33. (April 2004). "Lipoic acid is 10 times more toxic in cats than reported in humans, dogs or rats". Journal of Animal Physiology and Animal Nutrition.
34. (August 1995). "Alpha-lipoic acid as a biological antioxidant". [[Free Radical Biology and Medicine]].
35. (October 2009). "Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential". [[Biochimica et Biophysica Acta (BBA) - General Subjects]].
36. (1991). "Scavenging of hypochlorous acid by lipoic acid". [[Biochemical Pharmacology (journal).
37. (2008). "Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects".
38. (August 1996). "Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase". [[Biochemical and Biophysical Research Communications]].
39. (April 2003). "Radiation response of cells during altered protein thiol redox". Radiation Research.
40. (1997). "Cytosolic and mitochondrial systems for NADH- and NADPH-dependent reduction of alpha-lipoic acid". [[Free Radical Biology and Medicine]].
41. (July 1995). "Reduction and transport of lipoic acid by human erythrocytes". [[Biochemical Pharmacology (journal).
42. (June 2006). "Cellular disulfide-reducing capacity: An integrated measure of cell redox capacity". [[Biochemical and Biophysical Research Communications]].
43. (July 2002). "Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells". [[Free Radical Biology and Medicine]].
44. (1994). "Stereospecific reduction of R(+)-thioctic acid by porcine heart lipoamide dehydrogenase/diaphorase". [[Zeitschrift für Naturforschung C]].
45. (1997). "Lipoic Acid In Health & Disease". [[CRC Press]].
46. (2008). "Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects".
47. (May 2010). "Sulforaphane and alpha-lipoic acid upregulate the expression of the pi class of glutathione S-transferase through c-jun and Nrf2 activation". [[Journal of Nutrition]].
48. (June 2008). "Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity". IUBMB Life.
49. (August 1960). "Studies on the in vivo metabolism of lipoic acid. 1. The fate of DL-lipoic acid-S35 in normal and thiamine-deficient rats". [[Archives of Biochemistry and Biophysics]].
50. (July 1965). "Reversal of selective toxicity of (-)-alpha-lipoic acid by thiamine in thiamine-deficient rats". [[Nature (journal).
51. "Pharmaceutical compositions containing R-alpha-lipoic acid or S-alpha.-lipoic acid as active ingredient".
52. (October 1995). "Modelling cortical cataractogenesis 17: In vitro effect of a-lipoic acid on glucose-induced lens membrane damage, a model of diabetic cataractogenesis". Biochemistry and Molecular Biology International.
53. (September 2000). "Modulation by antioxidants of endothelial apoptosis, proliferation, & associated gene/protein expression". [[Diabetologia]].
54. (July 1997). "Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle". [[American Journal of Physiology.
55. (March 2004). "(r)-, but not (s)-alpha lipoic acid stimulates deficient brain pyruvate dehydrogenase complex in vascular dementia, but not in Alzheimer dementia". Journal of Neural Transmission.
56. (2011-01-01). "Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy". Therapeutics and Clinical Risk Management.
57. (1999). "α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany". Experimental and Clinical Endocrinology & Diabetes.
58. (November 2008). "Lipoic Acid". [[American Cancer Society]].
59. (2024-01-29). "Ranking Alpha Lipoic Acid and Gamma Linolenic Acid in Terms of Efficacy and Safety in the Management of Adults With Diabetic Peripheral Neuropathy: A Systematic Review and Network Meta-analysis". Canadian Journal of Diabetes.
60. (April 2012). "Treatment for mitochondrial disorders". Cochrane Database Syst Rev.
61. (2018). "Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials". Clinical Nutrition.
62. Talaverón-Rey, M., Reche-López, D., Povea-Cabello, S. et al. Alpha–lipoic acid supplementation improves pathological alterations in cellular models of Friedreich ataxia. Orphanet J Rare Dis 20, 453 (2025). https://doi.org/10.1186/s13023-025-03990-z